{
    "Clinical Trial ID": "NCT00036270",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Exemestane",
        "  Exemestane (Aromasin\u00ae) 25 mg QD for 5 years.",
        "INTERVENTION 2: ",
        "  Tamoxifen Followed by Exemestane",
        "  Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.",
        "  Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.",
        "Exclusion Criteria:",
        "  Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:",
        "  Inflammatory breast cancer",
        "  Histologically positive supraclavicular nodes",
        "  Ulceration/infiltration of local skin metastasis",
        "  Neoadjuvant chemotherapy",
        "  Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion",
        "  ER and PR negative primary tumor or ER/PR unknown status."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years",
        "  Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.",
        "  Time frame: Baseline (Month 0) up to 2.75 years",
        "Results 1: ",
        "  Arm/Group Title: Exemestane",
        "  Arm/Group Description: Exemestane (Aromasin  ) 25 mg QD for 5 years.",
        "  Overall Number of Participants Analyzed: 4898",
        "  Measure Type: Number",
        "  Unit of Measure: Events (disease relapse or death)  352",
        "Results 2: ",
        "  Arm/Group Title: Tamoxifen Followed by Exemestane",
        "  Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.",
        "  Overall Number of Participants Analyzed: 4868",
        "  Measure Type: Number",
        "  Unit of Measure: Events (disease relapse or death)  388"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 784/4814 (16.29%)",
        "  Anaemia * 5/4814 (0.10%)",
        "  Anaemia vitamin B12 deficiency * 1/4814 (0.02%)",
        "  Coagulopathy * 1/4814 (0.02%)",
        "  Febrile neutropenia * 0/4814 (0.00%)",
        "  Haemorrhagic anaemia * 0/4814 (0.00%)",
        "  Iron deficiency anaemia * 1/4814 (0.02%)",
        "  Leukocytosis * 1/4814 (0.02%)",
        "  Leukopenia * 1/4814 (0.02%)",
        "  Lymphadenopathy * 1/4814 (0.02%)",
        "  Neutropenia * 0/4814 (0.00%)",
        "Adverse Events 2:",
        "  Total: 831/4852 (17.13%)",
        "  Anaemia * 12/4852 (0.25%)",
        "  Anaemia vitamin B12 deficiency * 0/4852 (0.00%)",
        "  Coagulopathy * 0/4852 (0.00%)",
        "  Febrile neutropenia * 2/4852 (0.04%)",
        "  Haemorrhagic anaemia * 1/4852 (0.02%)",
        "  Iron deficiency anaemia * 0/4852 (0.00%)",
        "  Leukocytosis * 0/4852 (0.00%)",
        "  Leukopenia * 1/4852 (0.02%)",
        "  Lymphadenopathy * 3/4852 (0.06%)",
        "  Neutropenia * 1/4852 (0.02%)"
    ]
}